|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng H, Zheng R, Guo Y, Zhang S, Zou X,
Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in
China, 2003–2005: A population-based study. Int J Cancer.
136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fu J and Wang H: Precision diagnosis and
treatment of liver cancer in China. Cancer Lett. 412:283–288. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whitehurst AW: Cause and consequence of
cancer/testis antigen activation in cancer. Annu Rev Pharmacol
Toxicol. 54:251–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ha JH, Yan M, Gomathinayagam R, Jayaraman
M, Husain S, Liu J, Mukherjee P, Reddy EP, Song YS and Dhanasekaran
DN: Aberrant expression of JNK-associated leucine-zipper protein,
JLP, promotes accelerated growth of ovarian cancer. Oncotarget.
7:72845–72859. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jagadish N, Gupta N, Agarwal S, Parashar
D, Sharma A, Fatima R, Topno AP, Kumar V and Suri A:
Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor
growth of triple-negative breast cancer cells. Tumour Biol.
37:13101–13110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiao C, Fu L, Yan C, Shou F, Liu Q, Li L,
Cui S, Duan J, Jin G, Chen J, et al: SPAG9 is overexpressed in
osteosarcoma, and regulates cell proliferation and invasion through
regulation of JunD. Oncol Lett. 12:2674–2679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ren B, Wei X, Zou G, He J, Xu G, Xu F,
Huang Y, Zhu H, Li Y, Ma G, et al: Cancer testis antigen SPAG9 is a
promising marker for the diagnosis and treatment of lung cancer.
Oncol Rep. 35:2599–2605. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miao ZF, Wang ZN, Zhao TT, Xu YY, Wu JH,
Liu XY, Xu H, You Y and Xu HM: Overexpression of SPAG9 in human
gastric cancer is correlated with poor prognosis. Virchows Arch.
467:525–533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren B, Zou G, He J, Huang Y, Ma G, Xu G,
Li Y and Yu P: Sperm-associated antigen 9 is upregulated in
hepatocellular carcinoma tissue and enhances QGY cell proliferation
and invasion in vitro. Oncol Lett. 15:415–422.
2018.PubMed/NCBI
|
|
11
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shankar S, Mohapatra B, Verma S, Selvi R,
Jagadish N and Suri A: Isolation and characterization of a haploid
germ cell specific sperm associated antigen 9 (SPAG9) from the
baboon. Mol Reprod Dev. 69:186–193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cuadrado A and Nebreda AR: Mechanisms and
functions of p38 MAPK signalling. Biochem J. 429:403–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu W, Xu C, Wan H, Liu C, Wen C, Lu H and
Wan F: MicroRNA-206 overexpression promotes apoptosis, induces cell
cycle arrest and inhibits the migration of human hepatocellular
carcinoma HepG2 cells. Int J Mol Med. 34:420–428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan J, Yu H, Guo Z, Liu Q, Ding M, Xu K
and Mao L: Emerging role of sperm-associated antigen 9 in
tumorigenesis. Biomed Pharmacother. 103:1212–1216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan Q, Lou G, Qian Y, Qin B, Xu X, Wang Y,
Liu Y and Dong X: SPAG9 is involved in hepatocarcinoma cell
migration and invasion via modulation of ELK1 expression. Onco
Targets Ther. 9:1067–1075. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie C, Fu L, Liu N and Li Q:
Overexpression of SPAG9 correlates with poor prognosis and tumor
progression in hepatocellular carcinoma. Tumour Biol. 35:7685–7691.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren B, Luo S, Xu F, Zou G, Xu G, He J,
Huang Y, Zhu H and Li Y: The expression of DAMP proteins HSP70 and
cancer-testis antigen SPAG9 in peripheral blood of patients with
HCC and lung cancer. Cell Stress Chaperones. 22:237–244. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsiao CC, Chen PH, Cheng CI, Tsai MS,
Chang CY, Lu SC, Hsieh MC, Lin YC, Lee PH and Kao YH: Toll-like
receptor-4 is a target for suppression of proliferation and
chemoresistance in HepG2 hepatoblastoma cells. Cancer Lett.
368:144–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rohrabaugh S, Kesarwani M, Kincaid Z,
Huber E, Leddonne J, Siddiqui Z, Khalifa Y, Komurov K, Grimes HL
and Azam M: Enhanced MAPK signaling is essential for CSF3R induced
leukemia. Leukemia. 31:1770–1778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee CM, Onésime D, Reddy CD, Dhanasekaran
N and Reddy EP: JLP: A scaffolding protein that tethers JNK/p38MAPK
signaling modules and transcription factors. Proc Natl Acad Sci
USA. 99:14189–14194. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jagadish N, Rana R, Selvi R, Mishra D,
Garg M, Yadav S, Herr JC, Okumura K, Hasegawa A, Koyama K and Suri
A: Characterization of a novel human sperm-associated antigen 9
(SPAG9) having structural homology with c-Jun N-terminal
kinase-interacting protein. Biochem J. 389:73–82. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Win S, Than TA, Zhang J, Oo C, Min RWM and
Kaplowitz N: New insights into the role and mechanism of
c-Jun-N-terminal kinase signaling in the pathobiology of liver
diseases. Hepatology. 67:2013–2024. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seki E, Brenner DA and Karin M: A liver
full of JNK: Signaling in regulation of cell function and disease
pathogenesis, and clinical approaches. Gastroenterology.
143:307–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grossi V, Peserico A, Tezil T and Simone
C: p38α MAPK pathway: A key factor in colorectal cancer therapy and
chemoresistance. World J Gastroenterol. 20:9744–9758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang SN, Lee KT, Tsai CJ, Chen YJ and Yeh
YT: Phosphorylated p38 and JNK MAPK proteins in hepatocellular
carcinoma. Eur J Clin Invest. 42:1295–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hsieh SC, Huang MH, Cheng CW, Hung JH,
Yang SF and Hsieh YH: α-Mangostin induces mitochondrial dependent
apoptosis in human hepatoma SK-Hep-1 cells through inhibition of
p38 MAPK pathway. Apoptosis. 18:1548–1560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jilg CA, Ketscher A, Metzger E, Hummel B,
Willmann D, Rüsseler V, Drendel V, Imhof A, Jung M, Franz H, et al:
PRK1/PKN1 controls migration and metastasis of androgen-independent
prostate cancer cells. Oncotarget. 5:12646–12664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Yan L, Cao M, Zhang H, Li C, Bai
Y, Yu P, Li M and Zhao X: SPAG9 promotes endometrial carcinoma cell
invasion through regulation of genes related to the
epithelial-mesenchymal transition. Eur J Gynaecol Oncol.
37:312–319. 2016.PubMed/NCBI
|
|
31
|
Sinha A, Agarwal S, Parashar D, Verma A,
Saini S, Jagadish N, Ansari AS, Lohiya NK and Suri A: Down
regulation of SPAG9 reduces growth and invasive potential of
triple-negative breast cancer cells: Possible implications in
targeted therapy. J Exp Clin Cancer Res. 32:692013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stramucci L, Pranteda A and Bossi G:
Insights of crosstalk between p53 protein and the MKK3/MKK6/p38
MAPK signaling pathway in cancer. Cancers. 10:E1312018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baldari S, Ubertini V, Garufi A, D'Orazi G
and Bossi G: Targeting MKK3 as a novel anticancer strategy:
Molecular mechanisms and therapeutical implications. Cell Death
Dis. 6:e16212015. View Article : Google Scholar : PubMed/NCBI
|
